Showing results (2261-2270 of 2,317) with videos related to
Sort By:
Pageof 232
JTO Clinical and Research Reports|January 3, 2022
Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN StudyXue-Ning Yang, Hong-Hong Yan, Jun Wang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 7, 2018
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)Song-Tao Xu, Jun-Jie Xi, Wen-Zhao Zhong, et al.Bioorganic Chemistry|March 2, 2018
4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacyShu-Yu Lin, Teng-Kuang Yeh, Jen-Shin Song, et al.Lipids in Health and Disease|July 22, 2025
Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trialXianyou Ji, Jinlan Xia, Hong Zhang, et al.Nature Neuroscience|November 7, 2018
Partial loss of psychiatric risk gene Mir137 in mice causes repetitive behavior and impairs sociability and learning via increased Pde10aYing Cheng, Zhi-Meng Wang, Weiqi Tan, et al.The Lancet. Respiratory Medicine|December 21, 2020
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.Lung Cancer (Amsterdam, Netherlands)|November 13, 2020
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) studyJian Zeng, Wei-Min Mao, Qi-Xun Chen, et al.Cancer Communications (London, England)|November 4, 2022
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapyFengying Wu, Tao Jiang, Gongyan Chen, et al.Blood Advances|April 20, 2023
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm studyLi-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2020
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III TrialWen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.Pageof 232